Human Gut-Derived Akkermansia Strain 'AKK PROBIO®' Completes FDA NDI Notification, a World First
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
AKK PROBIO®, a human gut-derived Akkermansia muciniphila strain developed by Microfood Co., Ltd., has become the first in the world to complete the FDA's New Dietary Ingredient (NDI) notification process. This milestone confirms its safety and scientific backing, strengthening its position in the North American market.
AI Analysis
Frequently Asked Questions
- Q: What does FDA NDI notification for AKK PROBIO® mean?
- A: It means the ingredient has been reviewed for safety as a new dietary ingredient in the U.S., with no safety concerns raised.
- Q: What's the difference between live and heat-killed types?
- A: Live strains may colonize the gut, while heat-killed strains still deliver functional benefits without viability.
- Q: Can I purchase in Japan?
- A: Yes, Microfood Co., Ltd. is the exclusive distributor with domestic inventory in Japan.
- Q: What were the clinical trial results?
- A: In a 160-person trial, live strain reduced body fat by ~1kg, and heat-killed increased GLP-1 by ~20%.
- Q: Can it be used for OEM development?
- A: Yes, Microfood offers formulation support and quality assurance for OEM product development.